ProCyte (US) secures marketing rights to Hymedix' Hypan
This article was originally published in Clinica
ProCyte (US) has received worldwide marketing rights (outside Asia) to five of Hymedix International's Hypan polymer-based wound care products. Cleared by the US FDA, they include transparent thin film wound dressings, aquagel sheet dressings, exudate absorbers and wound moisturisers. The agreement with Hymedix (US) includes an up-front cash and common stock payment, plus future cash/royalty payments.